MARKET

INTS

INTS

INTENSITY THERAPEUTICS INC
NASDAQ
0.4700
-0.1200
-20.34%
After Hours: 0.4664 -0.0036 -0.77% 19:59 12/12 EST
OPEN
0.5995
PREV CLOSE
0.5900
HIGH
0.6000
LOW
0.4201
VOLUME
7.04M
TURNOVER
--
52 WEEK HIGH
3.166
52 WEEK LOW
0.1853
MARKET CAP
28.23M
P/E (TTM)
-0.7366
1D
5D
1M
3M
1Y
5Y
1D
Intensity Therapeutics To Present SABCS Posters Highlighting INVINCIBLE‑4 TNBC Safety Data With 50% Fewer Grade ≥3 AEs And Phase 3 Design Overview For INT230‑6
Benzinga · 2d ago
Intensity Therapeutics to present two posters ay SABCS
TipRanks · 2d ago
Intensity Therapeutics Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial
Reuters · 2d ago
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Barchart · 3d ago
Weekly Report: what happened at INTS last week (1201-1205)?
Weekly Report · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
Reuters · 12/05 19:14
BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret
Reuters · 12/05 14:22
BUZZ-Intensity Therapeutics jumps after Nasdaq grants compliance extension
Reuters · 12/05 12:40
More
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.

Webull offers Intensity Therapeutics Inc stock information, including NASDAQ: INTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INTS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INTS stock methods without spending real money on the virtual paper trading platform.